Adjuvant therapy for ampullary carcinomas: The Mayo Clinic experience

Sumita Bhatia, Robert C. Miller, Michael Haddock, John H. Donohue, Sunil Krishnan

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Purpose: To determine the effects of adjuvant radiotherapy and chemotherapy for carcinoma of the ampulla of Vater. Methods and Materials: We retrospectively reviewed the records of 125 patients who underwent definitive surgery for carcinomas involving the ampulla of Vater between April 1977 and February 2005 and who survived more than 50 days after surgery. Twenty-nine of the patients also received adjuvant radiotherapy (median dose, 50.4 Gy in 28 fractions) with concurrent 5-fluorouracil chemotherapy. Adverse prognostic factors were investigated, and overall survival (OS) and local and distant failure were estimated. Results: Adverse prognostic factors for decreased OS by univariate analysis included lymph node (LN) involvement, locally advanced tumors (T3/T4), and poor histologic grade. By multivariate analysis, positive LN status (p = 0.02) alone was associated with decreased OS. The addition of adjuvant radiotherapy and chemotherapy improved OS for patients with positive LN (p = 0.01). Median survival for positive LN patients receiving adjuvant therapy was 3.4 years, vs. 1.6 years for those with surgery alone. Conclusions: The addition of adjuvant radiotherapy and 5-fluorouracil chemotherapy may improve OS in patients with LN involvement. The effect of adjuvant therapy on outcomes for patients with poor histologic grade or T3/T4 tumors without LN involvement could not be assessed.

Original languageEnglish (US)
Pages (from-to)514-519
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume66
Issue number2
DOIs
StatePublished - Oct 1 2006

Fingerprint

lymphatic system
therapy
Adjuvant Radiotherapy
Lymph Nodes
cancer
chemotherapy
Carcinoma
radiation therapy
Survival
surgery
Ampulla of Vater
Adjuvant Chemotherapy
Fluorouracil
grade
Therapeutics
tumors
Drug Therapy
Survival Analysis
Ambulatory Surgical Procedures
Neoplasms

Keywords

  • Ampulla of Vater
  • Ampullary
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Adjuvant therapy for ampullary carcinomas : The Mayo Clinic experience. / Bhatia, Sumita; Miller, Robert C.; Haddock, Michael; Donohue, John H.; Krishnan, Sunil.

In: International Journal of Radiation Oncology Biology Physics, Vol. 66, No. 2, 01.10.2006, p. 514-519.

Research output: Contribution to journalArticle

Bhatia, Sumita ; Miller, Robert C. ; Haddock, Michael ; Donohue, John H. ; Krishnan, Sunil. / Adjuvant therapy for ampullary carcinomas : The Mayo Clinic experience. In: International Journal of Radiation Oncology Biology Physics. 2006 ; Vol. 66, No. 2. pp. 514-519.
@article{c52de6de4f6045688827754960072d98,
title = "Adjuvant therapy for ampullary carcinomas: The Mayo Clinic experience",
abstract = "Purpose: To determine the effects of adjuvant radiotherapy and chemotherapy for carcinoma of the ampulla of Vater. Methods and Materials: We retrospectively reviewed the records of 125 patients who underwent definitive surgery for carcinomas involving the ampulla of Vater between April 1977 and February 2005 and who survived more than 50 days after surgery. Twenty-nine of the patients also received adjuvant radiotherapy (median dose, 50.4 Gy in 28 fractions) with concurrent 5-fluorouracil chemotherapy. Adverse prognostic factors were investigated, and overall survival (OS) and local and distant failure were estimated. Results: Adverse prognostic factors for decreased OS by univariate analysis included lymph node (LN) involvement, locally advanced tumors (T3/T4), and poor histologic grade. By multivariate analysis, positive LN status (p = 0.02) alone was associated with decreased OS. The addition of adjuvant radiotherapy and chemotherapy improved OS for patients with positive LN (p = 0.01). Median survival for positive LN patients receiving adjuvant therapy was 3.4 years, vs. 1.6 years for those with surgery alone. Conclusions: The addition of adjuvant radiotherapy and 5-fluorouracil chemotherapy may improve OS in patients with LN involvement. The effect of adjuvant therapy on outcomes for patients with poor histologic grade or T3/T4 tumors without LN involvement could not be assessed.",
keywords = "Ampulla of Vater, Ampullary, Radiotherapy",
author = "Sumita Bhatia and Miller, {Robert C.} and Michael Haddock and Donohue, {John H.} and Sunil Krishnan",
year = "2006",
month = "10",
day = "1",
doi = "10.1016/j.ijrobp.2006.04.018",
language = "English (US)",
volume = "66",
pages = "514--519",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Adjuvant therapy for ampullary carcinomas

T2 - The Mayo Clinic experience

AU - Bhatia, Sumita

AU - Miller, Robert C.

AU - Haddock, Michael

AU - Donohue, John H.

AU - Krishnan, Sunil

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Purpose: To determine the effects of adjuvant radiotherapy and chemotherapy for carcinoma of the ampulla of Vater. Methods and Materials: We retrospectively reviewed the records of 125 patients who underwent definitive surgery for carcinomas involving the ampulla of Vater between April 1977 and February 2005 and who survived more than 50 days after surgery. Twenty-nine of the patients also received adjuvant radiotherapy (median dose, 50.4 Gy in 28 fractions) with concurrent 5-fluorouracil chemotherapy. Adverse prognostic factors were investigated, and overall survival (OS) and local and distant failure were estimated. Results: Adverse prognostic factors for decreased OS by univariate analysis included lymph node (LN) involvement, locally advanced tumors (T3/T4), and poor histologic grade. By multivariate analysis, positive LN status (p = 0.02) alone was associated with decreased OS. The addition of adjuvant radiotherapy and chemotherapy improved OS for patients with positive LN (p = 0.01). Median survival for positive LN patients receiving adjuvant therapy was 3.4 years, vs. 1.6 years for those with surgery alone. Conclusions: The addition of adjuvant radiotherapy and 5-fluorouracil chemotherapy may improve OS in patients with LN involvement. The effect of adjuvant therapy on outcomes for patients with poor histologic grade or T3/T4 tumors without LN involvement could not be assessed.

AB - Purpose: To determine the effects of adjuvant radiotherapy and chemotherapy for carcinoma of the ampulla of Vater. Methods and Materials: We retrospectively reviewed the records of 125 patients who underwent definitive surgery for carcinomas involving the ampulla of Vater between April 1977 and February 2005 and who survived more than 50 days after surgery. Twenty-nine of the patients also received adjuvant radiotherapy (median dose, 50.4 Gy in 28 fractions) with concurrent 5-fluorouracil chemotherapy. Adverse prognostic factors were investigated, and overall survival (OS) and local and distant failure were estimated. Results: Adverse prognostic factors for decreased OS by univariate analysis included lymph node (LN) involvement, locally advanced tumors (T3/T4), and poor histologic grade. By multivariate analysis, positive LN status (p = 0.02) alone was associated with decreased OS. The addition of adjuvant radiotherapy and chemotherapy improved OS for patients with positive LN (p = 0.01). Median survival for positive LN patients receiving adjuvant therapy was 3.4 years, vs. 1.6 years for those with surgery alone. Conclusions: The addition of adjuvant radiotherapy and 5-fluorouracil chemotherapy may improve OS in patients with LN involvement. The effect of adjuvant therapy on outcomes for patients with poor histologic grade or T3/T4 tumors without LN involvement could not be assessed.

KW - Ampulla of Vater

KW - Ampullary

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=33748327995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748327995&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2006.04.018

DO - 10.1016/j.ijrobp.2006.04.018

M3 - Article

C2 - 16863684

AN - SCOPUS:33748327995

VL - 66

SP - 514

EP - 519

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -